



Respiratory Syncytial Virus (RSV) Products Order Form

FAX COMPLETED FORM TO 905-465-3403

PHU Use Only

A temperature log with 30 most recent days must be included with the order if your facility has not ordered other vaccines within the same ordering cycle using the <u>online vaccine ordering system</u>.

Order No.:

Section 1: Facility Information

Facility	Name		Holding Po HAL_OK_			Date YYYY/MM/DD
Facility	Contact					
Last Na	me		First Name ₋			
Telepho	one No	x	Fax No		Email Address	
Facility Address						
Unit#	Street #	Street Name		City/Town	Province ON	e Postal Code
Reque	sted Deliver	y Method Orders will be	distributed ac	cording to the cur	rent <u>Vaccine Dis</u>	tribution Schedule*
Pick-up Tuesday Pick-up Wedne		esday	Delivery (only for	facilities with exist	ing courier arrangements)	

Section 2: Product and Eligibility Criteria

RSV Prevention Program for Infants and High-Risk Children							
Refer to the Ministry of Health for program eligibility details							
PRODUCT	INDICATION	# OF DOSES ON HAND	# OF DOSES REQUIRED				
Beyfortus® 50mg (Nirsevimab)	Infants < 5kg						
Beyfortus® 100mg (Nirsevimab)	Infants and high-risk children ≥ 5kg						
Abrysvo™	Pregnant individuals 32-36 weeks gestation, who will deliver during the RSV season. *Note that Nirsevimab is preferred over Abrysvo for the prevention of RSV in infants. Refer to NACI Statement on the Prevention of RSV Disease in Infants						



High-Risk Older Adult Program

Refer to the Ministry of Health for program eligibility details

**NOTE: If an individual has already received a dose of RSV vaccine in previous seasons, they <u>do not</u> need to receive another dose this season, as booster doses are not currently recommended.

PRODUCT	ELIGIBILITY CRITERIA	# OF DOSES ON HAND	# OF DOSES REQUIRED
Arexvy / Abrysvo™	All individuals <u>aged 75</u> and older.		
	Individuals 60 to 74 years of age who are also: Resident of a LTCH or Retirement Home In hospital receiving alternative level of care (ALC) including similar settings (e.g. complex continuing care, hospital transitional programs) Patients with glomerulonephritis (GN) who are moderately to severly immunocompormised. Experiencing homelesssness Identify as Fist Nations, Inuit or Métis Receving hemodialysis or peritoneal dialysis Vaccine to be adminstered by dialysis unit Recipents of solid organ or hematopotetic stem cell transplants Vaccine to be adminstered by translplant unit for patients currently under their care		

September 2025 Page 2 of 2